INTRODUCTION AND OBJECTIVES:
Radical prostatectomy is the recommended definitive surgical treatment for organ-confined prostate cancer in eligible men who meet the criteria for curative radical therapy. One of the main eligibility criteria is that the life expectancy should be at least 10 years. Compared to open surgery, whilst the reduction in the morbidity of surgery through robot-assisted radical prostatectomy (RARP) would intuitively suggest its potential advantage in the elderly, data specifically addressing its outcomes in the elderly are sparse. The aim of this study was to report on the safety (complications) and efficacy (oncological and functional outcomes) of RARP at our institution in those aged over 70.
METHODS RESULTS: Apart from Age (Mean AE SD years: 73.5 AE 2.1 versus 59.5 AE 5.9, p<0.001), the two groups were matched (all p-values >0.05) except for D'Amico grading which was higher in the Age !71 group. Median follow-up was 4.9 years. There were no 90-day mortalities in either group. were similar. On final pathology, a higher Gleason score (p[0.006) and higher stage (p<0.001) were observed in the Age!71 group. However, this did not translate adversely into a higher positive surgical margin, positive lymph node, biochemical relapse or cancer-specific mortality (p>0.05), allowing for the current follow-up duration (median 4.9 years). In terms of functional outcomes, there were no differences in post-operative erectile dysfunction (p[0.42). However, pad-free continence was significantly better in the younger cohort (p<0.001).
CONCLUSIONS: RARP should not be denied to those over 70 years solely on the basis of their age. Older men need to be counseled about the likelihood of encountering a higher rate of higher risk features on final pathology and that their pad-free continence may be lower compared to a younger person.
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INTRODUCTION AND OBJECTIVES: The Memorial Sloan
Kettering Cancer Center (MSKCC) Pre-Prostatectomy nomogram is a widely used resource that uses clinical factors to predict the likelihood of adverse pathology at radical prostatectomy. The increasing adoption of magnetic resonance imaging (MRI) targeted biopsy (TB) permits optimized detection of clinically-significant cancer over systematic biopsy alone. We aim to validate the prognostic utility of the MSKCC Pre-Prostatectomy nomogram with TB pathology results.
METHODS: Men who underwent systematic extended-sextant prostate biopsy (SB) and MRI TB who later underwent radical prostatectomy at our institution were included. Patient information was entered into the MSKCC Pre-Prostatectomy nomogram using five biopsy reporting schemes (SB alone, TB alone reported each of two ways (individual core (IC) technique or aggregate cores (AG) technique combining cores from a single MRI targeted lesion), and SB with TB combined with TB reported by both IC and AG methods. The likelihood of extraprostatic extension (EPE), lymph node involvement (LNI), and seminal vesicle invasion (SVI) as predicted by the nomogram for each biopsy reporting schema were compared to radical prostatectomy pathology.
RESULTS: We identified 63 men from January 2014 to November 2017. On ROC analysis, IC-TB, AG-TB, SB plus IC-TB, and SB plus AG-TB exhibited similar, if not improved, AUC compared to SB alone in predicting EPE (0.671, 0.674, 0.658, and 0.6613 versus 0.6085). For LNI, superior AUC was observed for AG-TB (0.647) compared to IC-TB (0.571) and SB alone (0.524) Equivocal SVI prediction was observed for SB plus IC-TB compared to SB alone (0.727 versus 0.733).
CONCLUSIONS: Using TB pathology results either alone or combined with SB pathology results for the MSKCC Pre-Prostatectomy nomogram appears comparable, if not improved, in prognosticating adverse pathologic features on radical prostatectomy compared to using SB core data alone from which the nomogram was developed.
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